{"disease":{"id":"attr-amyloidosis","name":"attr amyloidosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06355934","title":"OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis","phase":"","overall_status":"RECRUITING","enrollment_count":52121,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04561518","title":"ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT05444920","title":"The Italian Transthyretin Amyloidosis Web-Network","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT06836011","title":"A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT06040567","title":"Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","phase":"","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06251778","title":"NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Paolo Milani","has_results":false},{"nct_id":"NCT06261216","title":"Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT06458374","title":"ATTR Cardiac Amyloidosis in a Selected Population","phase":"","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Helse Møre og Romsdal HF","has_results":false},{"nct_id":"NCT04276220","title":"Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"Steen Hvitfeldt Poulsen","has_results":false},{"nct_id":"NCT06015997","title":"Prevalence of ATTR Cardiac Amyloidosis in Patients Undergoing TAVR","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Jordan Collaborating Cardiology Group","has_results":false},{"nct_id":"NCT06186167","title":"Amyloidosis Incidence in High-Risk Cardiac Device Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Midwest Heart & Vascular Specialists","has_results":false},{"nct_id":"NCT02797847","title":"A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT04601051","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Intellia Therapeutics","has_results":false},{"nct_id":"NCT07314268","title":"ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04201418","title":"A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT06499064","title":"EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT03728634","title":"Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03336580","title":"A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Prothena Biosciences Limited","has_results":false},{"nct_id":"NCT05023889","title":"Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Austin Neuromuscular Center","has_results":false},{"nct_id":"NCT05040373","title":"Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT05505838","title":"Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}